NASDAQ:XGN
Exagen Inc. Stock News
$1.88
-0.0100 (-0.529%)
At Close: May 17, 2024
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
12:25pm, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agre
Exagen Inc. (XGN) Q4 2021 Earnings Call Transcript
02:00am, Wednesday, 23'rd Mar 2022 The Motley Fool
XGN earnings call for the period ending December 31, 2021.
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
08:30pm, Tuesday, 22'nd Mar 2022
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
08:06pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives a
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 22'nd Mar 2022
Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
08:05pm, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
09:05pm, Wednesday, 09'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life S
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
09:05pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
04:05pm, Tuesday, 08'th Mar 2022
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
10:40pm, Thursday, 24'th Feb 2022 Zacks Investment Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09:05pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, L
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
05:00pm, Sunday, 09'th Jan 2022 GlobeNewswire Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ: XGN ), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies. RA is estimated to affect approximately two million patients in the United States and be twice as prevalent in women as in men and can be difficult to manage due to the variability in treatment response from patient to patient. Therapeutic agent selection for RA patients remains a significant unmet need.
